Terms: = Thyroid cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
705 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring braf
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
3. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
4. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract] [Full Text] [Related]
5. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract] [Full Text] [Related]
6. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract] [Full Text] [Related]
7. Progress in long non-coding RNAs as prognostic factors of papillary thyroid carcinoma.
Zhu HN; Song DL; Zhang SN; Zheng ZJ; Chen XY; Jin X
Pathol Res Pract; 2024 Apr; 256():155230. PubMed ID: 38461693
[TBL] [Abstract] [Full Text] [Related]
8. A nomogram for predicting adverse pathologic features in low-risk papillary thyroid microcarcinoma.
Gong L; Li P; Liu J; Liu Y; Guo X; Liang W; Lv B; Su P; Liang K
BMC Cancer; 2024 Feb; 24(1):244. PubMed ID: 38389061
[TBL] [Abstract] [Full Text] [Related]
9. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.
Vedovatto S; Oliveira FD; Pereira LC; Scheffel TB; Beckenkamp LR; Bertoni APS; Wink MR; Lenz G
Cell Commun Signal; 2024 Feb; 22(1):145. PubMed ID: 38388432
[TBL] [Abstract] [Full Text] [Related]
10. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract] [Full Text] [Related]
11. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
12. thyroid cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract] [Full Text] [Related]
13. braf V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract] [Full Text] [Related]
14. A phase 1 study of triple-targeted therapy with braf, MEK, and AKT inhibitors for patients with braf-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract] [Full Text] [Related]
15. Identification of a novel genomic variance of braf1 in papillary thyroid carcinoma: A case report.
Wang Y; Zhao J; Tan Z; Du J; Zhang L; Xu Y; Li X; Cai Y; Wang H; Jiang J
Medicine (Baltimore); 2024 Jan; 103(3):e36978. PubMed ID: 38241570
[TBL] [Abstract] [Full Text] [Related]
16. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for braf
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
17. Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.
Morand GB; Tessler I; Noik M; Krasner J; Yamin T; Pusztaszeri MP; Avior G; Payne RJ
Endocr Pract; 2024 Apr; 30(4):319-326. PubMed ID: 38184241
[TBL] [Abstract] [Full Text] [Related]
18. [Diagnostic Value of American thyroid Association Guidelines,American College of Radiology thyroid Imaging Reporting and Data System,and Chinese thyroid Imaging Reporting and Data System Alone and Combined With braf
Lin Y; Luo YK; Li J; Ren XY; Wang HW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
[TBL] [Abstract] [Full Text] [Related]
19. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
20. Establishment and Characterization of Amitrole-Induced Mouse thyroid Adenomatous Nodule-Derived Cell Lines.
Shirai YT; Hoshi N; Ward JM; Liu H; Cachau RE; Lee MP; Kimura S
Thyroid; 2024 Apr; 34(4):496-509. PubMed ID: 38149583
[No Abstract] [Full Text] [Related]
[Next]